Proposed settlements with world’s dominant railway equipment suppliers will provide $48.95 million for employees who alleged their compensation was adversely impacted by an agreement between Knorr and Wabtec not to poach each other’s employees Lieff Cabraser Heimann & Bernstein, LLP and Fine, Kaplan and Black, R.P.C. announce a total of $48.95 million in settlements to
Kellum is Fourth Executive to Be Charged in Ongoing Investigation A former senior executive pleaded guilty today for his role in a conspiracy to fix prices, rig bids, and allocate customers for generic drugs, the Department of Justice has announced. According to court documents, from at least March 2013 until at least June 2015, Hector Armando
If You Bought or Provided Reimbursement for the Anticoagulant Medications Lovenox® or Generic Enoxaparin Between September 21, 2011 and September 30, 2015 You Could Get Money from Class Action Settlements Totaling $120 Million Proposed Settlements totaling $120 million have been reached in a class action lawsuit regarding the price that uninsured consumers, hospitals, and third-party
Lieff Cabraser serves as counsel for amicus AAI, who successfully secured denial of drug makers’ requested injunction against the new pro-competition law AB 824 Lieff Cabraser serves as counsel for amicus American Antitrust Institute, on whose behalf the firm filed a brief in opposition to drug makers’ attempts to enjoin a new California law (AB
$120 million aggregate settlement will benefit hospitals, insurers and companies that pay for their employees’ healthcare costs, and uninsured people affected by the pharma companies’ alleged anticompetitive conduct Lieff Cabraser is proud to announce that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have agreed to settlements totaling $120 million in the antitrust class action about enoxaparin,
As reported by Law360 (subscription), the parties in the Lovenox/Enox blood clot drug antitrust lawsuit have announced a $35 million settlement in the class action lawsuit brought on behalf of thousands of buyers of generic Lovenox (enoxaparin) that accused the company and Sandoz Pharmaceuticals of illegally conspiring to prevent other drug companies from competing in the
On September 23, 2019, Lieff Cabraser partner Dean M. Harvey participated in a public panel discussion presented by the Antitrust Division of the U.S. Department of Justice on “Competition in Labor Markets” at the DOJ Conference Center in Washington, D.C. The event featured a group of well-known antitrust and competition lawyers, experts, and scholars.
At its annual Antitrust Enforcement Awards dinner in Washington, D.C., the American Antitrust Institute formally presented its selection of leading legal practitioners and economists to be recognized as honorees for the 2019 Antitrust Enforcement Awards, a list that includes the Lieff Cabraser team that worked on the Duke/UNC case: Dean M. Harvey, Kelly M. Dermody, Brendan P. Glackin,
The American Antitrust Institute has announced its selection of leading legal practitioners and economists to be recognized as honorees for the 2019 Antitrust Enforcement Awards, a list that includes the Lieff Cabraser team that worked on the Duke/UNC case: Dean M. Harvey, Kelly M. Dermody, Brendan P. Glackin, and Anne B.
On September 24, 2019, the U.S. District Court Judge Catherine C. Eagles granted final approval to the proposed settlement of the Duke/UNC “No Poach” case valued at $54.5 million. The settlement includes an unprecedented role for the United States Department of Justice to monitor and enforce extensive injunctive relief. Assistant Attorney General Delrahim remarked: “Permitting the